BioNTech SE said on Friday it has been informed by its partner OncoC4 that the U.S. Food and Drug Administration has lifted ...

The recommended commercial dosage of UNLOXCYT is 1,200 mg administered as an intravenous infusion over 60 minutes every three weeks. Cutaneous squamous cell carcinoma (cSCC) is the second most common ...

Ashfaq Marghoob provides skin cancer care to the residents of Long Island at MSK’s dedicated skin cancer center in Hauppaugue. Most cases of squamous cell carcinoma can be cured when found early and ...

No writing assistance was utilized in the production of this manuscript. Ocular surface squamous neoplasia is the most common nonpigmented ocular surface lesion. Ocular surface squamous neoplasia ...

Unloxcyt was approved by the FDA as a new treatment for patients with locally advanced or metastatic cutaneous squamous cell ...

UNLOXCYT (cosibelimab-ipdl) is indicated for the treatment of adults with metastatic cutaneous squamous cell carcinoma (“cSCC”) or locally advanced cSCC who are not candidates for curative surgery or ...

Squamous cancer is a heterogeneous disease with unique genomic and phenotypic features that differ markedly between individual patients and result in major differences in disease course and response ...

Surgical, radiation and medical oncologists in the Baylor St. Luke's Medical Center Dan L Duncan Comprehensive Cancer Center specialize in the diagnosis and treatment of head and neck squamous cell ...

Ocular surface squamous neoplasia (OSSN) consists of a wide range of conjuctival and corneal lesions ranging from dysplastic lesions to invasive squamous cell carcinoma. A number of risk factors ...

With new data on petosemtamab set to be presented at the European Society for Medical Oncology Asia Congress, Merus believes ...